Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-OX40 agonist monoclonal antibody BAT6026

An agonistic recombinant monoclonal antibody that recognizes the co-stimulatory receptor OX40 (CD134; tumor necrosis factor receptor superfamily member 4; TNFRSF4), with potential immunostimulatory activity. Upon administration, anti-OX40 agonist monoclonal antibody BAT6026 selectively targets, binds to and activates OX40. This may induce the proliferation of memory and effector T lymphocytes and inhibit the function of T-regulatory cells (Tregs) in the tumor microenvironment (TME). This enhances anti-tumor immune responses and prevents Tregs-mediated immune suppression. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T lymphocytes and plays an essential role in T-cell activation and differentiation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:agonistic anti-OX40 monoclonal antibody BAT6026
Code name:BAT 6026
BAT-6026
BAT6026
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search